Related Experiment Video
Updated: Mar 11, 2026
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Liver Metastases From Noncolorectal Malignancies (Neuroendocrine Tumor, Sarcoma, Melanoma, Breast)
Erica S Alexander1, Michael C Soulen
1From the Division of Interventional Radiology, University of Pennsylvania, Philadelphia, PA.
Abstract:
Patients with noncolorectal hepatic metastases often face limited treatment options and a dismal prognosis. Over the last decade, the advent of targeted immunotherapies has transformed the treatment of certain metastatic cancers, such as sarcoma and melanoma; however, these patients eventually develop resistance. Metastatic sarcoma, melanoma, and breast and neuroendocrine tumors are notoriously treatment resistant once they have metastasized to the liver. For these cancers, minimally invasive transarterial and ablation therapies have emerged as safe, palliative therapies that can provide symptom control and even prolong survival.
Insights
Treatments for liver metastases from sarcoma, melanoma, and other cancers are limited. Minimally invasive therapies like transarterial and ablation offer palliative care, symptom control, and potentially longer survival for these resistant cancers.
Area of Science:
- Oncology
- Interventional Radiology
Background:
- Noncolorectal hepatic metastases present limited therapeutic options and poor prognoses.
- Targeted immunotherapies have improved outcomes for some metastatic cancers but resistance eventually develops.
- Metastatic sarcoma, melanoma, breast, and neuroendocrine tumors are particularly resistant to systemic therapies when confined to the liver.
Purpose of the Study:
- To review the role of minimally invasive transarterial and ablation therapies for noncolorectal hepatic metastases.
- To highlight these therapies as palliative options for treatment-resistant liver cancers.
Main Methods:
- Literature review of transarterial and ablation therapies for hepatic metastases.
- Analysis of safety and efficacy data for palliative treatment of resistant cancers.
Main Results:
- Minimally invasive transarterial and ablation therapies are emerging as safe palliative options.
- These interventions can provide effective symptom control for patients with advanced liver disease.
- Evidence suggests these methods may also contribute to prolonged survival.
Conclusions:
- Transarterial and ablation therapies represent valuable palliative strategies for noncolorectal hepatic metastases.
- These minimally invasive approaches offer hope for symptom management and survival extension in treatment-resistant cases.
